Published in Expert Rev Clin Pharmacol on March 28, 2014
Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis (2015) 1.04
Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update. J Clin Transl Hepatol (2016) 0.93
Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration. Toxicol Sci (2014) 0.91
Pain management in ambulatory surgery-a review. Pharmaceuticals (Basel) (2014) 0.87
Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. Clin Pharmacol (2015) 0.86
On-chip three-dimensional cell culture in phaseguides improves hepatocyte functions in vitro. Biomicrofluidics (2015) 0.80
Risk of Acute Kidney Injury and Long-Term Outcome in Patients With Acetaminophen Intoxication: A Nationwide Population-Based Retrospective Cohort Study. Medicine (Baltimore) (2015) 0.77
Carnosic acid protects against acetaminophen-induced hepatotoxicity by potentiating Nrf2-mediated antioxidant capacity in mice. Korean J Physiol Pharmacol (2015) 0.77
AMPK Activation Prevents and Reverses Drug-Induced Mitochondrial and Hepatocyte Injury by Promoting Mitochondrial Fusion and Function. PLoS One (2016) 0.76
Glycyrrhizin Protects against Acetaminophen-Induced Acute Liver Injury via Alleviating Tumor Necrosis Factor α-Mediated Apoptosis. Drug Metab Dispos (2016) 0.75
Enolate-Forming Phloretin Pharmacophores: Hepatoprotection in an Experimental Model of Drug-Induced Toxicity. J Pharmacol Exp Ther (2016) 0.75
A long-term, open-label safety study of single-entity hydrocodone bitartrate extended release for the treatment of moderate to severe chronic pain. J Pain Res (2014) 0.75
Osteoarthritis: Yet another death knell for paracetamol in OA. Nat Rev Rheumatol (2016) 0.75
Effect of Acetaminophen Ingestion on Thermoregulation of Normothermic, Non-febrile Humans. Front Pharmacol (2016) 0.75
Co-administration of fresh grape fruit juice (GFJ) and bergamottin prevented paracetamol induced hepatotoxicity after paracetamol overdose in rats. Toxicol Rep (2015) 0.75
Acetaminophen (Paracetamol) Induces Hypothermia During Acute Cold Stress. Clin Drug Investig (2017) 0.75
[Injection treatment with hyaluronic acid]. Z Rheumatol (2015) 0.75
The return on investment in health care: from 1980 to 2000. Value Health (2006) 3.81
Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol (2006) 3.18
Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States. Pain Med (2014) 1.79
Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation (2008) 1.56
The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States. Qual Life Res (2008) 1.11
Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pain Pract (2010) 1.02
Cost, morbidity, and control of asthma in Hungary: The Hunair Study. J Asthma (2003) 1.02
A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther (2002) 1.00
Economic costs of obesity to self-insured employers. J Occup Environ Med (2008) 0.99
Can managed care organizations partner with manufacturers for comparative effectiveness research? Am J Manag Care (2008) 0.97
Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics (2009) 0.95
Hepatitis B in pregnancy: challenges and treatment. Gastroenterol Clin North Am (2011) 0.95
The impact of overweight and obesity on the direct medical costs of truck drivers. J Occup Environ Med (2009) 0.94
Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ (2014) 0.89
The efficacy and tolerability of perampanel and other recently approved anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis. Curr Med Res Opin (2013) 0.88
Use of prescription opioids with abuse-deterrent technology to address opioid abuse. Curr Med Res Opin (2014) 0.86
Health economics perspective of the components of the cardiometabolic syndrome. J Clin Hypertens (Greenwich) (2010) 0.84
Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract (2011) 0.84
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry (2003) 0.81
Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ (2011) 0.81
A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator. J Asthma (2005) 0.80
Sources of prescription opioids among diagnosed opioid abusers. Curr Med Res Opin (2015) 0.79
Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis. Clin Ther (2012) 0.79
Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting. J Asthma (2005) 0.79
Association between cardiometabolic risk factors and body mass index based on diagnosis and treatment codes in an electronic medical record database. J Manag Care Pharm (2008) 0.78
Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. Pain Pract (2011) 0.78
Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data. Appl Health Econ Health Policy (2014) 0.78
The cost-effectiveness of the levonorgestrel-releasing intrauterine system for the treatment of idiopathic heavy menstrual bleeding in the United States. Value Health (2013) 0.78
Characteristics of High-Cost Patients Diagnosed with Opioid Abuse. J Manag Care Spec Pharm (2015) 0.78
Evaluation of resource utilization and cost burden before and after an employer-based migraine education program. J Occup Environ Med (2009) 0.78
Impact of body mass index on the incidence of cardiometabolic risk factors in ambulatory care settings over 5 years or more. Value Health (2009) 0.77
Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans. J Med Econ (2014) 0.76
US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system. Curr Med Res Opin (2014) 0.75
Health-care resource use by asthmatics in Croatia. J Asthma (2002) 0.75
Predicting medication persistence to buprenorphine transdermal system. Pain Pract (2014) 0.75
Use of the SF-36v2 Health Survey as a Screen for Risk of Major Depressive Disorder in a US Population-based Sample and Subgroup With Chronic Pain. Med Care (2017) 0.75
National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom. Int J Cardiol (2003) 0.75
The economic burden of diagnosed opioid abuse among commercially insured individuals. Postgrad Med (2014) 0.75
Direct-to-consumer advertising: its effects on stakeholders. J Allied Health (2008) 0.75
Cardiometabolic risk and health care utilization and cost for Hispanic and non-Hispanic women. Popul Health Manag (2009) 0.75